Home - Chinese Journal of Cancer Research

2022 Impact Factor of CJCR: 5.1
Journal Citation Reports ™, Clarivate Analytics

National Health Commission guidelines for diagnosis and treatment of colorectal cancer 2023 in China (English version)

National Health Commission of the People’s Republic of China; Society of Oncology, Chinese Medical Association

CSCO guidelines for colorectal cancer version 2023: Updates and insights

Colorectal cancer (CRC) is the second most common cancer and the most common type of gastrointestinal cancer with rapidly increasing incidence and mortality in China. Since the first edition of the Chinese Society of Clinical Oncology (CSCO) guideline was published in 2017, the guideline has been updated annually according to the latest results of clinical research at home and abroad, the accessibility of drugs and the opinions of CSCO experts. Here, we present the main updates of the 2023 version compared to the 2022 version.

Stomach cancer burden in China: Epidemiology and prevention

In 2020, stomach cancer was the fifth most commonly diagnosed cancer and the fourth leading cause of cancer-related death worldwide. Due to the relatively huge population base and the poor survival rate, stomach cancer is still a threat in China, and accounts for nearly half of the cases worldwide. Fortunately, in China, the incidence and mortality rates of stomach cancer presented a declining trend owing to the change of individual life styles and the persistent efforts to prevent stomach cancer from the governments at all levels. Helicobacter pylori (H. pylori) infection, poor eating habits, smoking, history of gastrointestinal disorders, and family history of stomach cancer are the main risk factors for stomach cancer in China. As a result, by taking risk factors for stomach cancer into account, specific preventive measures, such as eradicating H. pylori and implementing stomach cancer screening projects, should be taken to better prevent and decrease the burden of stomach cancer.

Burden of liver cancer: From epidemiology to prevention

In this review, we offer a concise overview of liver cancer epidemiology in China and worldwide from the official databases of GLOBOCAN 2020 and the National Cancer Registry in China. We also summarized the evidence for the main risk factors associated with liver cancer risk and discuss strategies implemented in China to control the liver cancer burden. Overall, liver cancer was the sixth most commonly diagnosed cancer and the third leading cause of cancer-related death worldwide in 2020. Although China contributed to nearly half of cases across the world alone, the incidence and mortality rates of liver cancer presented a declining trend owing to the persistent efforts from the governments at all levels. The current liver cancer burden in China still faces an arduous challenge due to the relatively large population base as well as the substantially low survival rate (12.1%). To better control the liver cancer burden with the lowest cost, specific measures should be conducted by reducing exposure to established risk factors such as hepatitis B infection and aflatoxin.

‹ ›

Vol 35, No 3 (June 2023)

Review Article

Application of single-cell RNA sequencing in head and neck squamous cell carcinoma

Zhaohong An, Wan Liu, Wenbin Li, Minghui Wei, Changming An

Pages: 331-342 HTML

Research progress of minimally invasive surgery for gastric cancer

Hao Su, Zhaode Bu

Pages: 343-353 HTML

Original Article

Impact of preoperative therapy on surgical outcomes of laparoscopic total gastrectomy for gastric/gastroesophageal junction cancer

Yuehong Chen, Zhijing Yang, Mingli Zhao, Chuanjin Xu, Yuxuan Zhu, Huimin Zhang, Huilin Huang, Yanmei Peng, Yanfeng Hu, Tian Lin, Tao Chen, Hao Chen, Liying Zhao, Hao Liu, Guoxin Li, Jiang Yu, Xinhua Chen

Pages: 354-364 HTML

Striatins and STRIPAK complex partners in clinical outcomes of patients with breast cancer and responses to drug treatment

Amber Xinyu Li, Jimmy Jianyuan Zeng, Tracey A Martin, Lin Ye, Fiona Ruge, Andrew J Sanders, Elyas Khan, Q. Ping Dou, Eleri Davies, Wen G Jiang

Pages: 365-385 HTML

Sarcopenia and gut microbiota alterations in patients with hematological diseases before and after hematopoietic stem cell transplantation

Boshi Wang, Wei Hu, Xue Zhang, Yanchao Cao, Lin Shao, Xiaodong Xu, Peng Liu

Pages: 386-398 HTML

Efficacy and safety of anlotinib as an adjuvant therapy in hepatocellular carcinoma patients with a high risk of postoperative recurrence

Jianguo Wang, Xiaonan Xiang, Zhixiong Shi, Hui Zhang, Quanbao Zhang, Zhikun Liu, Guangjie Zhao, Chuanxing Wu, Qiang Wei, Lin Zhong, Zhengxin Wang, Guoyue Lv, Shusen Zheng, Xiao Xu

Pages: 399-407 HTML

Detection and classification of breast lesions using multiple information on contrast-enhanced mammography by a multiprocess deep-learning system: A multicenter study

Yuqian Chen, Zhen Hua, Fan Lin, Tiantian Zheng, Heng Zhou, Shijie Zhang, Jing Gao, Zhongyi Wang, Huafei Shao, Wenjuan Li, Fengjie Liu, Simin Wang, Yan Zhang, Feng Zhao, Hao Liu, Haizhu Xie, Heng Ma, Haicheng Zhang, Ning Mao

Pages: 408-423 HTML

Perspective

Focal ablation therapy presents promising results for selectively localized prostate cancer patients

Dechao Feng, Dengxiong Li, Yuhan Xiao, Ruicheng Wu, Jie Wang, Chi Zhang

Pages: 424-430 HTML

NHCPRC Guidelines

National Health Commission guidelines for diagnosis and treatment of colorectal cancer 2023 in China (English version)

National Health Commission of the People’s Republic of China; Society of Oncology, Chinese Medical Association

Pages: 197-232 HTML